Sponsor study identifier
interventional
40
1 country
1
Study Start
April 2, 2025
Actual (reported)Primary Completion
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2, 2025
Actual (reported)April 7, 2025
Actual (reported)April 13, 2025
Actual (reported)October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Evaluation of safety and tolerability
Safety to be measured via occurrence and severity of adverse events
Through 1 year from administration
Characterize pharmacokinetic profile
Through 1 year from administration
Evaluate immunogenicity
Through 1 year from administration
IDB-011 dose level 1
IDB-011 dose level 2
IDB-011 dose level 3
IDB-774 + IDB-898
IDB-774 + IDB-898
Altasciences Clinical Los Angeles
Cypress, California, 90630, United States
First Submitted
April 7, 2025
First Posted
April 13, 2025
Study Start
April 2, 2025
Actual (reported)Primary Completion
October 2026
EstimatedSafety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
IDB-011 dose level 4
IDB-011 dose level 5
Normal saline
IDB-774 + IDB-898
IDB-774 + IDB-898
IDB-774 + IDB-898
Normal saline
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 25, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: